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Abstract 
Background: There continues to be a great need for better biomarkers and host‑directed treatment targets for 
community‑acquired pneumonia (CAP). Alterations in phospholipid metabolism may constitute a source of small 
molecule biomarkers for acute infections including CAP. Evidence from animal models of pulmonary infections and 
sepsis suggests that inhibiting acid sphingomyelinase (which releases ceramides from sphingomyelins) may reduce 
end‑organ damage.
Methods: We measured concentrations of 105 phospholipids, 40 acylcarnitines, and 4 ceramides, as well as acid 
sphingomyelinase activity, in plasma from patients with CAP (n = 29, sampled on admission and 4 subsequent time 
points), chronic obstructive pulmonary disease exacerbation with infection (COPD, n = 13) as a clinically important 
disease control, and 33 age‑ and sex‑matched controls.
Results: Phospholipid concentrations were greatly decreased in CAP and normalized along clinical improvement. 
Greatest changes were seen in phosphatidylcholines, followed by lysophosphatidylcholines, sphingomyelins and cer‑
amides (three of which were upregulated), and were least in acylcarnitines. Changes in COPD were less pronounced, 
but also differed qualitatively, e.g. by increases in selected sphingomyelins. We identified highly accurate biomark‑
ers for CAP (AUC ≤ 0.97) and COPD (AUC ≤ 0.93) vs. Controls, and moderately accurate biomarkers for CAP vs. COPD 
(AUC ≤ 0.83), all of which were phospholipids. Phosphatidylcholines, lysophosphatidylcholines, and sphingomyelins 
were also markedly decreased in S. aureus‑infected human A549 and differentiated THP1 cells. Correlations with 
C‑reactive protein and procalcitonin were predominantly negative but only of mild‑to‑moderate extent, suggesting 
that these markers reflect more than merely inflammation. Consistent with the increased ceramide concentrations, 
increased acid sphingomyelinase activity accurately distinguished CAP (fold change = 2.8, AUC = 0.94) and COPD 
(1.75, 0.88) from Controls and normalized with clinical resolution.
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Background
Community-acquired pneumonia (CAP) is the sixth 
most common cause of death worldwide and is a major 
burden on healthcare resources [1]. According to recent 
reports, the overall annual incidence of CAP in Europe is 
1.2 per 1000 persons and it increases with age to 14 per 
1000 person a year in adults aged ≥ 65  years [2]. There 
have been intense efforts to identify host biomarkers for 
CAP [3, 4]. These studies have been geared predomi-
nantly toward identifying biomarkers to [1] aid in early 
diagnosis, for instance to distinguish between viral and 
bacterial etiologies to improve antibiotic stewardship, [2] 
determine more accurately the required duration of ther-
apy, and [3] improve risk stratification and prediction of 
clinical outcome. Another important goal of biomarker 
profiling of patient biosamples is to study pathogenesis, 
e.g. by elucidating molecular pathways that are strongly 
associated with a disease state and may constitute targets 
for patient-directed adjunct treatments to improve out-
come, for instance by reducing end-organ damage.
Lipids are involved in a variety of processes inti-
mately connected with the pathogenesis of pneumonia 
and related infectious diseases. For instance, mem-
brane lipids are crucial players in intracellular signaling 
events that are found across immune cells and resident 
lung cells, e.g. signaling due to phospholipases which 
release bioactive molecules such as fatty acids (e.g., 
arachidonic acid), sphingolipids and lysophosphati-
dylcholines (lysoPC) and their derivatives [5]. Choles-
terol, sphingomyelins (SM) and phosphatidylcholines 
(PC) are involved in the formation of the immunologi-
cal synapse, and lipids play important roles in mac-
rophage activation [6], NK cell function 2011 [7], and 
differentiation and activity of T and B effector cells [8, 
9]. Lipid-mediated signaling has also been shown to be 
involved in regulating processes intimately associated 
with inflammation- and infection-associated end-organ 
and cell damage, notably apoptosis, autophagy [10], and 
pulmonary fibrosis [11]. In particular, ceramides are 
considered to be proinflammatory lipids in lung epithe-
lium, and pharmacological inhibition of their synthesis 
by acid sphingomyelinase may reduce organ damage 
due to reactive oxygen species and inflammation in 
mouse models of sepsis [12, 13] and Pseudomonas 
aeruginosa infection in cystic fibrosis [14]. Moreover, 
intracellular oxidation of saturated lipids and cera-
mides by reactive oxygen species leads to the synthesis 
of peroxides and induces ferroptosis [15]. Considering 
these and other pieces of evidence, it has recently been 
suggested that acid sphingomyelinase could serve as a 
treatment target not just for cystic fibrosis [16] but for 
a range of bacterial infections [17]. Acylcarnitines (AC) 
are fatty acids covalently bound to carnitine, which are 
imported into mitochondria where the fatty acid is used 
for energy generation via beta-oxidation. Increased AC 
concentrations in plasma have been associated with 
organ damage and mortality in sepsis [18], suggesting 
that they may play similar roles in CAP as well. Lastly, 
significantly decreased concentrations of lysoPC have 
been found in CAP [19, 20].
Considering these intimate connections between 
lipids and processes relating to the pathogenesis of 
pneumonia, it is conceivable that changes in plasma 
lipid populations can be mined for biomarker discov-
ery. In addition, identification of disease-associated 
metabolites and their biosynthetic pathways could 
potentially lead to the development of adjunct, host-
directed treatments aiming to reduce end-organ dam-
age and to improve clinical outcome. We have therefore 
applied a targeted lipidomic screen and an assay for 
acid sphingomyelinase activity to plasma samples from 
(1) patients with CAP during acute presentation and 
convalescence, (2) COPD exacerbation with suspected 
infection as a clinically potentially similar disease of 
different etiology (“disease control”), and (3) age- and 
sex-matched control subjects, and aimed to (1) assess 
global changes in plasma lipid populations and iden-
tify specific biomarkers for a diagnosis of CAP (also in 
contrast to COPD exacerbation) and for its clinical res-
olution and (2) test whether increased acid sphingomy-
alinase activity in peripheral blood is a feature of these 
disorders. In addition, we used a cellular model of S. 
aureus infection to test whether any observed changes 
in plasma phospholipid concentrations might originate 
Conclusions: The results underscore the high potential of plasma phospholipids as biomarkers for CAP, begin to 
reveal differences in lipid dysregulation between CAP and infection‑associated COPD exacerbation, and suggest that 
the decreases in plasma concentrations are at least partially determined by changes in host target cells. Furthermore, 
they provide validation in clinical blood samples of acid sphingomyelinase as a potential treatment target to improve 
clinical outcome of CAP.
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at the level of infected or inflammation-exposed host 
cells.
Methods, materials and participants
Study design and study population
This was a prospective, hospital-based study conducted 
at Otto-von-Guericke-University Hospital (Magde-
burg, Germany) and Hospital Clinic (Barcelona, Spain) 
between March 2014 and November 2015. We recruited 
patients (age ≥ 18 years) with CAP (n = 29) or COPD 
exacerbation with suspected infection (n = 13), both 
requiring hospitalization, and an age- and sex-matched 
control group [n = 33, consisting of structural or degen-
erative orthopedic disorders (n = 28) and healthy vol-
unteers (n = 5)] without systemic inflammation as 
evidenced by clinical and laboratory findings. All partici-
pants provided written informed consent. The study was 
conducted according to the Helsinki Declaration and was 
approved by the respective Ethics Committees (Otto-
von-Guericke University Magdeburg: file no. 36/14; Hos-
pital Clinic Barcelona: file no. HCB 2013/8396). Inclusion 
criteria for CAP were (1) evidence of pulmonary infiltrate 
on chest X-ray, (2) presence of at least two of the follow-
ing four symptoms: cough, purulent sputum production, 
dyspnea, pleuritic chest pain, (3) at least two vital sign 
abnormalities out of fever/hypothermia, hypotension, 
tachycardia, tachypnea, (4) one out of hypoxemia, evi-
dence of pulmonary consolidation, leukocytosis or leu-
kopenia, and (5) need for inpatient treatment as judged 
by the examining physician. Inclusion criteria for COPD 
exacerbation with suspected infection were (1) docu-
mented history of COPD, (2) sudden deterioration in res-
piratory status/lung function, and (3) symptoms (increase 
in sputum production, cough) and/or laboratory abnor-
malities (increased CRP and/or detection of a respiratory 
pathogen) suggestive of an infectious trigger or coexist-
ing airway infection. Exclusion criteria were a diagnosis 
of cancer or a chronic inflammatory disease (e.g., rheu-
matoid arthritis). Co-existing pneumonia was not an 
exclusion criterion for COPD, but it was not detected in 
any of the 13 participants in this group. At baseline (day 
(d)1), the following parameters were assessed in CAP and 
COPD: medical history, lung function tests, chest radio-
graph, vital signs (heart rate, blood pressure and body 
temperature), complete blood count, liver and kidney 
chemistry, and blood gas analysis. Furthermore, clinical 
data and blood samples were collected on d 2 and 4, and 
at two follow-up visits (1–14 days (f1) and 4–6 weeks (f2) 
after completion of antibiotic treatment). Nasal/pharyn-
geal swabs, sputum, urine and additional blood samples 
were collected and subjected to microbiological analy-
sis as clinically indicated. Blood samples from Controls 
were obtained once. All biosamples were collected and 
stored according to international biobanking standards 
(DIN EN ISO 9001:2008) and unified SOPs were used for 
all samples. Plasma C-reactive protein (CRP) and proc-
alcitonin (PCT) levels were measured in all samples in 
a single batch after conclusion of recruitment. CRP was 
measured nephelometrically on the Dimension VISTA 
1500 platform, using commercially available reagents 
and calibrators (Siemens Healthcare GmbH, Eschborn, 
Germany). The PCT assay was purchased from Thermo 
Fisher (Dreieich, Germany) and performed on the Cen-
taur XPT immunochemistry analyzer (Siemens Health-
care GmbH, Eschborn, Germany).
Lipidomic profiling
Concentrations of 145 lipids (76 PC, 14 lysoPC, 15 SM, 
and 40 AC) were measured with the  AbsoluteIDQ® 
p180 kit (Biocrates, Life Science AG, Innsbruck, Aus-
tria) by direct flow injection analysis using a triple-quad-
rupole mass spectrometer (AB Sciex,  QTRAP® 6500). 
Extraction of metabolites and all analytical assays were 
performed according to the manufacturer’s recommen-
dations (UM_p180_ABSciex_11 and Application Note 
1003-1, Biocrates Life Science AG, Innsbruck, Austria). 
Peak integration and calculation of metabolite concen-
trations were performed with the MetIDQ™ software 
tool (Biocrates Life Science AG, Innsbruck, Austria). The 
following nomenclature was used: sphingomyelin = SM; 
hydroxysphingomyelin = SM (OH); phosphatidylcho-
line = PC; aa = both side chains are fatty acids linked 
to a glycerol backbone by ester bonds; ae = one of the 
side chains is a fatty alcohol linked to the glycerol back-
bone by an ether bond; Cx:y; x = total number of car-
bon atoms and y = total number of double bonds in the 
side chains. In order to investigate the extent of repro-
gramming across classes of lipid molecules or selected 
enzyme activities, the MetIDQ™ Ratio Explorer software 
tool (Biocrates Life Sciences, [21]) was used to define 47 
“metabolic indicators” (Additional file  1: Table  S1), i.e. 
the sums of mean concentrations of biochemically related 
lipids (lipid classes, n = 11), ratios involving one or two 
lipid classes (n = 11), and ratios of specific lipid pairs 
(n = 25, 23 of which were custom-added to the Explorer 
for this study).
Targeted assays for ceramides
For the analysis shown in Fig.  6a–c, a liquid chroma-
tography (LC) coupled triple-quadrupole time-of-flight 
mass spectrometer (QTOF5600, Sciex) was used to quan-
tify selected ceramides. The ceramide standards C16:0 
(860516), C18:0 (860518), C24:0 (860524) and C24:1 
(860525) were purchased from Avanti polar lipids (Ala-
bama, US). Gradient-grade organic solvents and other 
chemicals included chloroform, methanol, and water 
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(9175, 9017, 8402, 4218, J.T. Baker), formic acid, ammo-
nium acetate, ammonium formate, dimethyl sulfoxide 
(06473, 55674, 70221, 472301 respectively, Sigma), and 
bovine serum albumin (BSA, 15269, ICN Biomedicals). A 
solution of pure analytes was injected into the machine 
for identification of individual masses and to obtain a 
chromatogram. The optimized MS settings were: gas 1: 
60 psi, gas 2: 75 psi, curtain gas: 45 psi, ion source tem-
perature: 400  °C, ion spray voltage floating: 4500  V and 
mass range: 50–1000  Da. An acquisition method was 
established in positive ion mode to ensure the accu-
rate identification of each analyte. The optimized HPLC 
parameters included: mobile phase; A, methanol/water 
(3/1, v/v, 1% formic acid, 20  mM ammonium formate); 
B, methanol/formic acid (99/1, v/v, 20  mM ammonium 
formate), column oven temperature 60 °C; mobile phase 
gradient: initial mobile phase was 80% B and the gradi-
ent was applied to attain 100% B within the first 10 min 
and the column was re-equilibrated for the last 3 min and 
flow rate of 0.7 ml/min. Metabolites were extracted using 
the classical Bligh and Dyer extraction protocol [22] with 
SM 17:0 as internal standard (ISTD). To assess perfor-
mance of this extraction protocol, plasma was spiked 
with ISTD in five replicates and extraction was per-
formed, followed by measurement of ISTD peak areas. A 
calibration curve in the concentration range from 0.02 to 
10 µM with an ISTD was prepared in BSA and injected 
into the LC–MS/MS system to estimate limit of detection 
(LOD) and lower limit of quantification.
Acid sphingomyelinase enzyme assay
Enzymatic activity in plasma samples was measured 
using the  Amplex® Red Sphingomyelinase Assay Kit (Inv-
itrogen) according to the manufacturer’s instructions. 
This assay is based on signal detection from a fluorescent 
product (resorufin) which is generated as an end product 
of the sphingomyelin cleavage reaction.
Infection of human cells with S. aureus
The myelomonocytic cell line THP1 was propagated 
in RPMI 1640 medium  (GIBCO® Life Technologies™) 
supplemented with 10% fetal bovine serum (FBS) 
and 2  mM  l-glutamine. To obtain differentiated cells 
(dTHP1), 5 × 106 THP1 cells/flask (T-75) in 25  ml of 
complete RPMI media were differentiated with 200  nM 
phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich, 
product no. P-8139) for 48 h and then incubated in fresh 
RPMI medium for another 24 h. 5 × 106 A549 (adenocar-
cinoma) cells were propagated in 25 ml complete DMEM 
medium supplemented with 10% FCS and 2  mM  l-glu-
tamine, and were allowed to settle for 24  h. Cells were 
infected with GFP-expressing S. aureus strain SH1000 at 
an MOI of 25 and incubated at 37 °C for 2 h. Cells were 
subsequently washed twice with PBS, and non-ingested 
bacteria were inactivated by adding gentamicin (100 µg/
ml) to the post-infection medium. Accutase solution was 
used to detach the A549 cells, whereas dTHP1 cells were 
detached with a cell scraper. Cells were then centrifuged 
to make a cell pellet, which was stored at − 80 °C. Frozen 
cell pellets were thawed on ice. 250 µl ice cold extraction 
solvent (ethanol/0.01  M phosphate buffer with 85/15, 
V/V) was used to re-suspend the cell pellet, which was 
then sonicated in an ice bath for 3 min. Liquid nitrogen 
was used for snap freezing. The sonicating/freezing/son-
icating cycles were repeated 3 times. The samples were 
then centrifuged for 5 min with 20,817g at 4 °C and lipid 
concentrations in the supernatant analyzed using the 
absoluteIDQ® p180 kit as described above for plasma.
Reanalysis of published gene expression data sets
Data sets from two studies featuring mRNA expres-
sion in CAP [23, 24] were accessed through GEO under 
accession numbers GSE40012 and 42830, respectively. 
Normalized expression values for the two isoforms of 
sphingomyelin phosphodiesterase 1 (SMPD1, OMIM: 
607608; also known as acid sphingomyelinase) were 
obtained using the GEO2R web tool [25] and significance 
of between-group expression differences assessed with 
the Mann–Whitney U test.
Statistical analysis
We included only those analytes with measured values 
above LOD of the  AbsoluteIDQ® p180 kit (as reported 
by the manufacturer) in at least 75% of the samples. Miss-
ing values were then replaced by imputation using linear 
regression models based on age, sex, disease state, and 
sample collection time point. The Mann–Whitney U 
test and Kruskal–Wallis H-test were used to assess sig-
nificance of differences between groups, with significance 
defined as a p value of < 0.05. The Benjamini–Hochberg 
correction was implemented to correct for multiple test-
ing using a false discovery rate (FDR) equal to 0.05. Sta-
tistical tests were performed using the open-source stats 
module of the Python’s SciPy statistic library (https ://
docs.scipy .org/doc/scipy /refer ence/stats .html) and the 
MNE-Python software package v0.18.1 (http://mne-tools 
.githu b.io/dev/index .html). For principal component anal-
ysis (PCA), data were standardized by removing the mean 
and scaling to unit variance and then analyzed using the 
scikit-learn Python  library for machine learning (https ://
sciki t-learn .org). Receiver operating characteristic (ROC) 
curves were computed by means of the function roc_
curve() of the sklearn.metrics module, using the logistic 
regression classifier in the sklearn.linear_model module 
with a stratified k-fold cross-validation (k = 5) repeated 25 
times to estimate the mean area under the curve (AUC) 
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and confidence intervals (CI). We defined biomarker can-
didates (for the sake of simplicity in the text referred to 
as biomarkers) as analytes with an AUC ≥ 0.80 (“excel-
lent classification” according to Hosmer and Lemeshow 
[26]), an asymptotic p value of < 0.05 (Mann–Whitney U 
test), and 95% confidence intervals (CI) not crossing the 
chance-line of AUC = 0.50. For linear fitting slope (LFS) 
analysis, the ratios of medians of each time-observation 
versus control were fitted to a linear function using the 
function polyfit() of the NumPy package for scientific 
computing (https ://www.numpy .org). Then, the distance 
of each ratio of medians to the fitted line was divided by 
the difference between the maximum and minimum ratio 
of medians, and the sum of the resulting values was then 
normalized by the number of observations (equal to 5), 
which is referred to as the normalized distance to fitting 
(NDF). Pearson correlation coefficients were obtained 
with the function pearsonr() of the scipy.stats module and 
used to assess correlations between metabolites and CRP 
and PCT. To assess the effect of sample size on biomarker 
discovery, increasing the size of the COPD group to that 
of CAP was modeled using the function RandomOver-
Sampler() in the imbalanced-learn package (https ://imbal 
anced -learn .readt hedoc s.io/en/stabl e/), which over-sam-




Table  1 summarizes sociodemographic and selected 
clinical characteristics of the three study groups. 
There were no significant differences in age and sex 
Table 1 Demographic, clinical and laboratory characteristics of the study population
CRP C-reactive protein, GOLD Global Initiative for Chronic Obstructive Lung Disease, NA not applicable, PCT procalcitonin, PSI Pneumonia Severity Index
a Kruskall–Wallis test
b Mann–Whitney U test (continuous variables),  Chi2 test (categorical variables)
CAP (n = 29) Infection-associated COPD 
exacerbation (n = 13)
Controls (n = 33) p value
All  groupsa CAP vs.  COPDb
Demographics
 Sex 
  Female (%) 38 46 36 0.30 0.25
  Male (%) 62 54 64
  Median age (range) 60 (24–90) 62 (55–81) 59 (24–90) 0.78 0.31
Medical history (past or current) 
 Diabetes (%) 38 17 24 2.0 × 10−03 9.0 × 10−04
 Cardiovascular disease (%) 28 50 24 1.6 × 10−04 1.4 × 10−03
 Cancer (%) 10 30 6 < 1.0 × 10−05 4.1 × 10−04
Treatment (at time of first blood sample)
 Antimicrobial (%) 100 100 0 NA NA
 Corticosteroid (%) 22 62 3.3 < 1.0 × 10−05 < 1.0 × 10−05
Disease severity
 PSI risk class (%) 
  I (low) 21 NA NA NA NA
  II (low) 20 NA NA NA NA
  III (low) 14 NA NA NA NA
  IV (moderate) 24 NA NA NA NA
  V (high) 21 NA NA NA NA
 GOLD grades (%)
  I (mild) NA 0 NA NA NA
  II (moderate) NA 25 NA NA NA
  III (severe) NA 25 NA NA NA
  IV (very severe) NA 50 NA NA NA
Laboratory results
 CRP (mg/l, ref. < 5 mg/l) 102 (3.1–428) 14 (3.1–91) 3.1 (3.1–7.1) 2.5 × 10−12 2.5 × 10−05
 PCT (ng/l, ref. < 0.5 ng/l) 0.23 (0.02–38) 0.09 (0.02–1.0) 0.02 (0.02–0.08) 5.0 × 10−09 7.1 × 10−03
 Pathogen detected (%) 41 54 NA NA NA
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among CAP, COPD, and Controls. All CAP and COPD 
patients received antimicrobial treatment either before 
hospital admission or were started on an antibiotic 
upon admission. Consistent with standard treatment, 
substantially more COPD than CAP patients were 
started on systemic corticosteroid treatment upon 
admission. Approximately 50% each of CAP patients 
had low (Pneumonia Severity Index [PSI], I–III) or 
moderate-to-high disease severity (PSI, IV–V, three of 
whom developed sepsis). One CAP patient was lost to 
follow-up after d4, but all 28 patients who returned for 
the f1 and/or f2 visits were in clinical remission at that 
time. Completeness of study visits and blood samples 
in CAP is summarized in Additional file  1: Table  S2. 
Disease activity in COPD (GOLD grade) was weighted 
more toward severe disease. Consistent with clinical 
experience, likely causative pathogens were detected 
in only about half of the cases. As expected, CRP and 
PCT concentrations were highest in CAP, intermedi-
ate in COPD, and normal in Controls. Thus, the CAP 
and COPD groups had the major clinical characteristics 
expected from the natural history of these disorders, 
but CAP also included several mild cases who were 
admitted to hospital according to the clinical judgment 
of the admitting or referring physician.
Metabolite detection across all samples
Of the 145 potentially detectable lipid analytes, measured 
concentrations of 111 (77%) were above LOD in ≥ 75% of 
the samples and were included in the subsequent analy-
ses (Additional file  1: Fig. S1A). Analyte detection was 
much more efficient for glycerophospholipids and sphin-
golipids than for acylcarnitines (Additional file  1: Fig. 
S1B). These results agreed well with information pro-
vided by the manufacturer of the MetIDQ™ p180 kit and 
published data [27, 28].
Changes in lipid populations are more extensive in CAP 
than in COPD and normalize with clinical recovery
Principal component analysis (PCA) was then used to 
test whether differences in the lipid profiles reflected 
the relationships expected from the clinical diagnoses, 
as well as clinical recovery in CAP (Fig. 1; the contribu-
tion of each lipid to the first and second principle com-
ponents is shown in Additional file 1: Fig. S2). The CAP 
baseline and COPD groups (d1) clustered distinctly away 
Fig. 1 Plasma lipid reprogramming is greater in CAP than COPD and normalizes in CAP with treatment. Principal component analysis (PCA) based 
either on concentrations of the 111 lipid analytes that passed the quality screen shown in this figure or on the 47 metabolic indicators. Each circle 
represents the centroid of all samples in the respective group/time point. a Analysis based on concentrations of all 111 lipid analytes; b lysoPC only; 
c PC only; d SM only; e AC only; f metabolic indicators. g Mean Euclidian distances on day 1 between CAP or COPD and Controls, based on all lipid 
analytes, each subclass, or on the metabolic indicators. Metabolites: AC, acylcarnitines; lysoPC, lysophosphatidylcholines; PC, phosphatidylcholines; 
SM, sphingomyelins
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from each other and from Controls, and analysis of CAP 
at subsequent time points revealed a “normalization” of 
lipid populations in CAP in that they clustered progres-
sively closer to Controls (Fig.  1a). Similar patterns were 
observed when profiles of the subclasses lysoPC (Fig. 1b), 
PC (Fig.  1c), and SM (Fig.  1d) were analyzed, whereas 
the relationships based on AC did not follow a discern-
able pattern (Fig. 1e). Analysis of the metabolic indicator 
patterns essentially confirmed the results based on the 
individual metabolites (compare Fig. 1f and a). The over-
all changes in lipid concentrations at baseline (as meas-
ured by Euclidian distance to Controls) were markedly 
greater in CAP than in COPD, and among the subgroups 
it was greatest in PC and lowest in AC (Fig.  1g). These 
results suggested a striking, higher degree of plasma lipid 
“reprogramming” in CAP than in COPD, which agreed 
well with the much higher degree of systemic inflamma-
tion (CRP, PCT) in CAP (Table 1).
Marked decrease in membrane phospholipids in CAP 
plasma
Concentrations of the majority of lipid analytes 
(85/111 = 77%) were significantly changed in CAP 
baseline (d1) with respect to Controls, most of which 
(83/85 = 98%) were downregulated, and all downregu-
lated analytes were membrane lipids, i.e. PC, lysoPC or 
SM (Fig.  2a). Only one AC (1/10 = 10%; C5) was differ-
entially abundant in CAP at baseline, but also (together 
with PCaeC36:0) constituted one of the only two upregu-
lated analytes. Consistent with the PCA shown in Fig. 1, 
lipid concentrations in CAP trended to “normalize” 
across the time course towards concentrations measured 
in Controls, but a substantial fraction of analytes did not 
normalize completely. Also, there were some clear dif-
ferences in the direction of concentration change (up 
vs. down) between COPD and CAP (Fig.  2a, b). Simi-
lar results were obtained with the metabolic indicators 
(Fig.  2c, d), which also revealed significantly elevated 
ratios of lysoPCaC16:0/C16:1 and lysoPCaC20:4/C20:3, 
likely indicating differences in conversion of the parent 
PCs by phospholipase A2, as direct (de)saturases that 
modify PC-bound fatty acids are not known. This analysis 
of metabolic indicators also revealed that changes in AC 
metabolism were somewhat more pronounced than sug-
gested by abundance data of individual analytes, as 5/16 
(31%) AC indicators were differentially regulated in CAP 
at baseline compared to Controls (Fig.  2c). In addition, 
a tendency toward changes in fatty acid oxidation for 
cell respiration was seen in COPD, as exemplified by an 
increased ratio of dicarboxylacylcarnitines/total acylcar-
nitines indicating increased utilization of ω-oxidation (a 
salvage pathway when β-oxidation is impaired) for ATP 
synthesis (Fig. 4f ).
Considering the well-documented property of CRP 
to bind to phospholipids [29], we investigated whether 
the downregulation observed above (Fig.  2a, b) was 
due to a technical artefact, i.e. the failure of our extrac-
tion procedure to capture phospholipids sequestered in 
complexes with CRP. In fact, adding increasing amounts 
of recombinant CRP to normal human plasma led to a 
trend towards increased concentrations, but clearly not 
to a decrease in any the four lipid classes (Additional 
file 1: Fig. S3). We then used S. aureus to infect human 
cell lines which represent important target cells in pneu-
monia (THP1 = monocytes; differentiated THP1 = mac-
rophages; A549 = respiratory epithelial cells) and then 
determined infection-associated changes in lipid popula-
tions (Fig. 3). Of note, similar to the decrease in plasma 
concentrations, S. aureus infection led to a significant 
decrease in all three phospholipid classes in dTHP1 cells, 
and PC and SM in A549 cells. In contrast, no change 
was observed in AC, whose plasma concentrations were 
not significantly decreased. These data suggest that 
changes of phospholipids in host cells that are infected 
or exposed to the associated inflammation may contrib-
ute to the observed decrease in phospholipid plasma 
concentrations.
Identification of diagnostic phospholipid biomarkers 
for CAP
Using binary ROC curve analysis, we then evaluated 
the biomarker potential of the lipid analytes and meta-
bolic indicators at baseline for each of the three pos-
sible paired diagnostic comparisons (Fig.  4, Additional 
Fig. 2 Massive decrease in phospholipid concentrations governs changes in plasma lipids in CAP. a Analysis based on the 111 lipid analytes and 47 
metabolic indicators. Data from COPD samples are displayed in the left column and CAP data in the right column. The lipid analytes are arranged 
in descending order according to ratio of median concentrations CAP d1/Controls (“fold change”). A major drop in membrane phospholipid 
concentrations is evident in CAP. b COPD only, same data as used in A, but showing differential expression in COPD, arranged in descending 
order according to fold change COPD vs Controls. c Analysis based on the 47 metabolic indicators. The indicators are ranked vertically according 
to descending ratio of median values in CAP d1/Controls (C). d COPD only, same data as used in C, but showing differential expression in COPD, 
arranged in descending order according to fold change COPD vs Controls. Differential expression (fold change) is expressed on a linear scale by 
the color scheme in the legend shown in a. Lipid classes are identified by the font colors identified in the legend. *p < 0.05, **p < 0.01, ***p < 0.001 
(Mann–Whitney U test). Δp < 0.05, ΔΔp < 0.01, ΔΔΔp < 0.001 (FDR‑corrected). Metabolite: AC, acylcarnitines; lysoPC, lysophosphatidylcholines; PC, 
phosphatidylcholines; SM, sphingomyelins. A comprehensive lipid nomenclature is detailed in “Methods, materials and participants”
(See figure on next page.)
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file  1: Table  S3). Not unexpectedly, the highest number 
of accurate biomarkers according to the three criteria 
(AUC ≥ 0.8, lower 95% CI ≥ 0.5, and p < 0.05) was found 
for the discrimination between CAP (baseline) and Con-
trols (n = 46 analytes, Fig. 4a), and a much lower number 
(n = 5) for the distinction COPD vs. Controls (Fig. 4b). Of 
note, four analytes fulfilling these criteria were identified 
even for the differentiation between the clinically rela-
tively closely related diagnoses CAP and COPD (Fig. 4c). 
Consistent with the heat maps shown in Fig.  2a, there 
was a strong trend toward decreased concentrations in 
the more inflamed group (i.e. CAP > COPD and Con-
trols; COPD > Controls) with respect to the less inflamed 
group; indeed, this was the case in all biomarkers fulfilling 
the three above criteria. As shown in detail in Additional 
file 1: Table S4, most of these biomarkers corresponded 
to PC (71%), followed by lysoPC (20%) and SM (9%), 
whereas there were no AC biomarkers. Assessing the 
biomarker potential within each class did reveal a higher 
potential of lysoPC in that a substantially higher per-
centage of lysoPC (10/13 = 77%) than PC (33/70 = 47%) 
constituted biomarkers according to the three criteria 
(Additional file 1: Table S4). Considering that much fewer 
biomarkers were identified for COPD, we tested whether 
this was due to the smaller sample size (13 COPD vs. 29 
CAP). An over-sampling method in which the COPD 
sample size was modeled to be 29 (i.e. the same as of 
CAP) yielded 13 biomarkers (Additional file 1: Table S5), 
which was a consequence of improved prediction accu-
racy of the model resulting in tighter AUC confidence 
intervals and a higher number of features with AUC 95% 
CI lower bound > 0.5. Thus, the lower biomarker poten-
tial of COPD was predominantly due to disease-specific 
differences and only to a minor extent due to the smaller 
sample size. Considering the higher percentage of COPD 
patients undergoing systemic corticosteroid therapy, 
we also tested whether the differences between CAP 
and COPD could be results of corticosteroid treatment. 
Fig. 3 Infection with S. aureus leads to downregulation of phospholipids in differentiated THP1 cells and A549 cells. Cells were infected with S. 
aureus strain SH1000 at an MOI of 25, harvested 2 h post infection, and lipids were then assayed using the same targeted lipidomic assays as for the 
human plasma samples. Values refer to mean fold concentration change with respect to uninfected cells. Bars = standard error of the mean (n = 3). 
a Phosphatidylcholines (PC). b Lysophosphatidylcholines (lysoPC). c Sphingomyelins (SM). d Acylcarnitines (AC). A549, adenocarcinoma cell line; 
THP1, myelomonocytic cell line; dTHP1, differentiated THP1 cells resembling human macrophages
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Fig. 4 Identification of diagnostic biomarkers by ROC curve analysis. Differential expression (ratio of medians, also referred to as “fold change”; 
y‑axis) is plotted against area under the ROC curve (AUC, x‑axis), with darkness of fill color indicating the asymptotic significance of the ROC curve. 
Each dot corresponds to one lipid analyte (a–c) or one metabolite indicator (d–f). The dotted vertical line highlights the cut‑off for “excellent 
classification” [26], i.e. AUC 0.80. a, d CAP baseline vs. Controls; b, e COPD vs. Controls; c, f CAP baseline vs. COPD The ROC analysis parameters of all 
markers with AUC ≥ 0.8 for each comparison are listed in Additional file 1: Table S2. g–l Levels of the most accurate biomarker for each of the three 
paired comparisons shown in a–f. g–i Best lipid biomarkers; PCaaC34:4 (CAP vs. CTRL), PCaaC42:6 (COPD vs. Control), lysoPCaC20:4 (CAP vs. COPD). 
j–l Best metabolic indicator biomarkers; Total lysoPC (CAP vs. Control), Total SM/Total PC (COPD vs Control), total SM (CAP vs. COPD). The box spans 
the 25th–75th percentile; lower whiskers = bottom quartile; upper whisker = upper quartile; and horizontal line = median. *p < 0.05, **p < 0.01, 
***p < 0.001 (Mann–Whitney U test). Metabolite: lysoPC, lysophosphatidylcholines; PC, phosphatidylcholines; SM, sphingomyelins
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However, multiple logistic regression analysis controlling 
for corticosteroid treatment did not reveal a significant 
effect (data not shown).
We also identified several metabolic indicators as 
accurate biomarkers for the differentiation between 
CAP vs. Controls (Fig.  4d), the five most accurate of 
which corresponded to the PC or lysoPC classes or 
ratios featuring them (Additional file 1: Table S3). Con-
sistent with a previous report of sphingolipid induc-
tion in COPD [30], total SM showed some potential to 
distinguish between COPD and Controls, but signifi-
cance was not achieved due to AUC CI crossing below 
0.5 (Fig.  4e, Additional file  1: Table  S3). However, due 
to the reciprocal regulation of total SM and some indi-
vidual SM in COPD (up) and CAP (down) observed in 
Fig. 2, higher total SM accurately distinguished COPD 
from CAP (Fig. 4f, Additional file 1: Table S3).
For each of the three diagnostic groups, absolute con-
centrations of the most accurate single biomarker for 
each of the three comparisons are shown in Fig.  4g–i, 
and values of the most accurate metabolic indicator bio-
marker in Fig. 4j–l. Taken together, these results agreed 
with the PCA (Fig. 1) in that lipid concentrations changed 
most significantly in CAP but that there were substantial 
differences even between CAP and COPD.
Normalization of lysoPC metabolism most closely parallels 
resolution of CAP
We then screened for changes in lipid concentrations and 
metabolic indicators in CAP throughout the time course 
that correlated best with resolution of inflammation and 
clinical improvement. In addition to clinical information 
(by which all patients with available blood samples had 
experienced resolution of symptoms by f1 and/or f2), the 
decline of CRP levels was used as a measure of inflam-
mation resolution. This screen led to the identification of 
several phospholipids (Fig. 5a, Additional file 1: Table S6) 
and two metabolic indicators that correlated with reso-
lution of CAP (Fig.  5b, Additional file  1: Table  S6). Of 
these, 6 lysoPC had the steepest slope towards normali-
zation, and the two metabolic indicators selected by this 
screen were based on lysoPC (Additional file 1: Table S6). 
Figure 5c–h illustrates the marked normalization of sys-
temic inflammation (CRP, PCT = panels c, d), concentra-
tions of the two best correlating phospholipid markers 
(lysoPCaC16:1 and lysoPCaC16:0 = panels e, f ), and val-
ues of the two best correlating metabolic indicators (total 
lysoPC and lysoPCaC16:0/C16:1 = g, h) across the time 
course. Thus, normalization of lysoPC metabolism most 
closely paralleled resolution of inflammation and clinical 
remission in CAP.
Increased ceramide synthesis and acid sphingomyelinase 
activity in CAP
Even though they were not found among the accurate 
biomarkers (as defined in “Methods, materials and par-
ticipants”), concentrations of some sphingomyelins (the 
precursors of ceramides) were decreased in CAP and, 
less so, in COPD. In addition, the close association of 
ceramide synthesis with inflammation has been well 
documented [12, 31]. We therefore used a dedicated 
mass spectrometry assay to measure concentrations of 
four ceramides which could potentially be derived from 
downregulated SM. Concentrations of ceramides C16:0, 
C18:0, and (less so) C24:1 were increased in CAP and 
normalized towards f2 (Fig.  6a–c), whereas no change 
was detected in C24:0 concentrations. Thus, even though 
there was a clear tendency toward increases in ceramides 
in CAP and COPD, distinct patterns were observed 
depending on the ceramide in question. Considering 
the potential conversion of SM to ceramides in CAP 
and, less so, COPD, we then tested whether activity of 
the corresponding enzyme, acid sphingomyelinase, was 
increased. Indeed, enzyme activity was 2.8-fold (median) 
higher in CAP than in Controls and normalized towards 
f2, whereas the increase in COPD was less pronounced 
(1.75-fold, median) (Fig.  6d). Of note, enzyme activ-
ity was an accurate biomarker for both CAP at baseline 
(AUC, 0.94 [0.81–1.0]) and COPD (AUC, 0.88 [0.62–1.0]) 
with respect to Controls. Since there are no other reports 
of acid sphingomyelinase activity in CAP to corroborate 
our finding, we interrogated published data sets of whole 
blood mRNA expression in different forms of CAP and 
control groups for expression of the acid sphingomyeli-
nase gene (sphingomyelin phosphodiesterase 1, SMPD1, 
OMIM: 607608). Indeed, expression of SMPD1 splic-
ing isoform 1 was significantly higher in bacterial CAP 
compared to controls and began to normalize during 
5  days of treatment (Fig.  6e), but expression of isoform 
2 was not significantly altered in bacterial CAP (data not 
shown) [23]. In contrast, in a different cross-sectional 
study, expression of both isoforms was elevated (Fig. 6f ) 
[24]. Of note, in the same study expression of both iso-
forms also decreased significantly after treatment of CAP 
(Fig. 6g). Thus, disease-relevant regulation of acid sphin-
gomyelinase expression in CAP was clearly evident also 
at the mRNA level.
Modest correlations with markers of systemic 
inflammation
We then performed a correlation analysis in CAP in 
order to test to what extent the lipids and metabolic 
indicators merely reveal processes already captured 
by CRP. Across all lipids there was a striking negative 
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correlation of the majority with CRP (79 of 111 [71%] 
lipids at p < 0.05) and PCT (69 of 111, 62%), with nega-
tive correlations with PCT tending to be weaker (Fig. 7a, 
Additional file  1: Table  S7). In particular, correlations 
of lysoPC and SM were exclusively negative (Fig. 7b, d), 
whereas the scattered positive correlations stemmed 
from PC (Fig.  7c), ceramides (Fig.  7e, Additional file  1: 
Table  S7), and AC (Fig.  7f ) and were of much smaller 
magnitude. Acid sphingomyelinase activity correlated 
moderately with both CRP (r = 0.29, p = 9.36E−04) and 
PCT concentrations (r = 0.29, p = 1.04E−03). Of note, 
the best biomarker for CAP identified with the ROC 
analysis (PCaaC34:4, Fig. 4a) correlated only moderately 
(r = − 0.51) with CRP (Additional file  1: Table  S7). Cor-
relations of the metabolic indicators also tended to be 
negative (Fig.  7g, Additional file  1: Table  S7), but com-
pared to the lipids the proportion of significant negative 
correlations were smaller for both CRP (21 of 44 [48%] 
correlations had p < 0.05) and PCT (13 of 44, 30%), as 
compared to the individual analytes. Thus, in spite of an 
obvious association with systemic inflammation (which is 
also, for instance, indicated in Fig. 5), the marked changes 
in lipid metabolism clearly also reflect other aspects of 
pathogenesis.
Discussion
We have performed a targeted metabolomic analysis of 
111 plasma lipids in CAP, which distinguishes itself from 
other lipidomic studies of CAP [19, 20] in that (1) com-
parisons were made against COPD exacerbation with 
infection as a clinically highly relevant disease control, 
(2) serial measurements were obtained in CAP allowing 
to assess changes in lipid concentrations during clinical 
Fig. 5 Selection of lipid biomarkers that correlate with resolution of CAP. A plot of linear fitting slope (y‑axis, LFS) vs. 1‑normalized distance to fitting 
(x‑axis, NDF) was used to identify lipid analytes (a) and metabolic indicators (b) that correlate best with resolution of CAP. (C‑H) Concentrations 
across the time course for CRP (c), PCT (d), the 2 best correlating lipids, lysoPCaC16:1 (e), lysoPCaC16:0 (f), and the 2 best correlating metabolic 
indicators, total lysoPC (g), lysoPCaC16:0/lysoPCaC16:1 (h). *p < 0.05, **p < 0.01, ***p < 0.001 (Mann–Whitney U test for paired comparisons, Kruskal–
Wallis H‑test for CAP d1 through CAP f2). Metabolite abbreviation: lysoPC, lysophosphatidylcholines
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recovery and resolution of inflammation, and (3) salient 
results were verified in a cellular infection model.
Marked decrease in plasma phospholipid concentrations
We observed a striking decrease of phospholipid con-
centrations in acute CAP, which by and large normalized 
with clinical recovery. The correlation analysis clearly 
showed that this is not merely a linear reflection of sys-
temic inflammation. There are different, not mutually 
exclusive, explanations for this downregulation. Firstly, 
it has been suggested that phospholipids can bind to 
acute phase reactants including CRP [29], but we have 
ruled out that this may lead to an artefactual decrease 
in our assay (Additional file 1: Fig. S3). Thus, subsequent 
removal of the complex (e.g. in the reticuloendothelial 
system) would be required in order to lead to reduced 
concentrations measured with our assay. Secondly, the 
balance between synthesis, incorporation into cell build-
ing blocks, release from cell turnover, and catabolism 
to downstream products may change greatly in acute 
infection. PCs can be hydrolyzed by phospholipase A2 
releasing one fatty acid and a lysoPC, which can then 
be hydrolyzed by lysophospholipase to yield another 
free fatty acid. Another explanation could be the oxida-
tion of phospholipid side chains. During oxidative stress 
and inflammation, polyunsaturated fatty acid side chains 
of membrane phospholipids can be modified  by oxida-
tion [32]. The best biomarkers for both CAP and COPD 
(Additional file 1: Table S3, Fig. 4) contain poly-unsatu-
rated fatty acids; for instance, PCaaC34:4 could contain 
arachidonic acid (C20:4), which can be oxidized to pros-
taglandins, i.e. well known players in the inflammatory 
response [33]. Indeed, the PCaaC34:4 that contains ara-
chidonic acid in addition to myristic acid (C14) makes 
of 37% of PCaaC34:4 species in human plasma [34]. 
Oxidized phospholipids can also bind to the scavenger 
receptor CD36 (a fatty acid translocase), be internalized 
into cells, and then serve as energy substrate for beta-oxi-
dation, for instance in T cells [35].
Decreased blood phospholipid concentrations have 
been documented in other invasive bacterial infections 
(bacteremia [36], sepsis [37]), and also in CAP [19, 20]. 
Fig. 6 Ceramide synthesis and acid sphingomyelinase activity are increased in CAP and COPD exacerbation. a Ceramide C 16:0, b ceramide C 
18:0, c ceramide C 24:1, d acid sphingomyelinase activity, measured with an in vitro assay based on separate aliquots from the plasma samples 
used for the mass‑spectrometric measurements. e–g Increased expression of SMPD1 (sphingomyelin phosphodiesterase, synonymous with acid 
sphingomyelinase) mRNA in CAP. Published datasets from studies on gene expression in CAP were reanalyzed for expression of SMPD1 mRNA as 
described in [47]. The mRNA expression data had been obtained with microarray analysis of whole blood. Y‑axis units correspond to normalized 
expression values. e Increased expression of splicing isoform 1 in community‑acquired bacterial CAP [23], available at GEO, accession no GSE40012. 
Diagnostic groups: Bacterial CAP (BAC), n = 16; influenza A virus CAP (IAV), n = 8; mixed infection CAP (mixed, n = 3); systemic inflammatory 
response syndrome (SIRS, n = 12); healthy donors (HD, n = 18). f, g Increased expression of splicing isoforms 1 and 2 in CAP at baseline (f) and 
decrease of both isoforms after treatment of CAP (g) [24], GEO accession no. 42830. Diagnostic groups in f: Ctrl (healthy controls, n = 38), CAP 
(n = 8). Diagnostic groups in g: CAP before and after treatment, n = 5 each. *p < 0.05, **p < 0.01, ***p < 0.001 (Mann–Whitney U test for paired 
comparisons)
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In particular, the recent study by Müller et al. [20] found 
markedly decreased lysoPC concentrations in CAP on 
admission, which normalized towards convalescence. 
These authors also demonstrated that the decreased 
lysoPC concentrations were neither due to metabolism 
by autotaxin nor reduced dietary intake during the acute 
illness. Furthermore, based on previous publications 
they suggested that the depressed lysoPC concentra-
tions may adversely affect host defenses in CAP and that 
pharmacologically raising them might be a host-directed 
treatment for CAP. In the present work, we show that 
the decreased phospholipid concentrations are not due 
to a technical artefact resulting from mere binding to 
CRP, but that phospholipid concentrations decrease 
in S. aureus infected human cells. This effect was most 
pronounced in dTHP1 cells, which resemble activated 
macrophages found in human tissues including the lung. 
Importantly, S. aureus infection did not affect AC con-
centrations, demonstrating that the infection did not 
exert a global effect on cellular lipids. Taken together, our 
data suggest that at least part of the observed decreased 
concentrations in plasma may be preprogrammed at 
the level of infected cells, for instance due to activity of 
phospholipases. We did not measure activity of enzymes 
other than acid sphingomyelinase, but it is conceivable 
that the final phospholipid concentrations result from an 
intricate network of intracellular and secreted enzymes. 
Our results partially differ from the bacteremia study by 
To et al., who used untargeted metabolomics and found 
elevated concentrations of lysoPC 18:1 (which was clearly 
downregulated in our study) and SM 18:0/16:0 (which 
were upregulated in COPD, but essentially unchanged 
in our study) in CAP [36]. These discrepancies may be 
due to differences in the detection assays, preanalytical 
sample processing, or in the clinical population. Clearly, 
much additional work is still needed to unravel the causes 
and consequences of depressed phospholipid concentra-
tions in CAP and other acute infections.
Implications of increased acid sphingomyelinase activity
Acid sphingomyelinase activity was markedly increased 
in CAP at baseline and decreased steadily throughout 
the time course, suggesting that the marked increase at 
presentation is clinically relevant. Sphingomyelins are 
ubiquitous cellular components and are involved in a 
variety of processes including cell division, cell prolifera-
tion and autophagy [38] and help to establish an equi-
librium between pro- and anti-inflammatory lipids and 
also to regulate immune responses in lung tissues [39], 
whereas ceramides are predominantly involved in inflam-
mation- and damage-associated processes [40]. Con-
centrations of 5/13 (38%) of the SM were not decreased, 
Fig. 7 Correlation analysis of lipid analytes or metabolic indicators for CAP d1 through f2 with CRP and PCT. Y‑axis values correspond to Pearson’s 
rho; significance of p values (Mann–Whitney U test) is indicated by the fill color of the circles. a 111 lipid analytes measured with the MetIDQ 
p180 kits. b lysopc; c PC; d SM; e ceramides (measured with targeted assays); f AC; and g metabolic indicators. Metabolite: AC, acylcaritines; Cer, 
ceramides; lysoPC, lysophosphatidylcholines; PC, phosphatidylcholines; SM, sphingomyelins
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but the sum of SM was significantly lower in CAP, sug-
gesting a broad effect upon SM concentrations. On the 
other hand, concentrations of only two of the four meas-
ured ceramides increased substantially in CAP. Consid-
ering that we profiled only a fraction of cellular SM and 
ceramides, and that there are several other enzymes that 
mediate ceramide synthesis [41], it is possible that the 
induction of ceramide synthesis is much more extensive 
than can be gleaned from our results. Pharmacological 
inhibition of acid sphingomyelinase in a mouse model of 
S. aureus sepsis reduced liver damage, pulmonary edema, 
and mortality [12, 13], inhaled sphingomyelinase inhibi-
tors reduced airway inflammation and Pseudomonas 
aeruginasa infection in a mouse model of cystic fibrosis 
[14], and this enzyme has thus been proposed as a tar-
get of host-directed treatments for bacterial infections 
and other inflammation-associated diseases [16, 17]. 
Our study now provides evidence of a clinically relevant 
increase in its activity in CAP and, thus, suggests acid 
sphingomyelinase as a potential target for host directed 
treatments to reduce end-organ damage in pneumonia. 
The increase in enzyme activity in COPD exacerbation 
was not as pronounced, but it is possible that acid sphin-
gomyelinase inhibition might also be promising for a sub-
group of COPD patients with the highest enzyme active, 
possibly manifested as unusually high ceramide levels.
Identification of diagnostic and correlative biomarkers 
for CAP
Our analysis revealed several highly accurate plasma lipid 
biomarkers for acute CAP as compared with Controls. 
The top 5 corresponded to PCs, which agreed well with 
the marked decrease observed in this class. It was not 
possible to compare their diagnostic accuracy to that of 
CRP because elevated CRP had been used as part of the 
case definition of CAP. However, the results do suggest 
that plasma phospholipids have strong biomarker poten-
tial for CAP, and future studies should be geared toward 
evaluating their ability to differentiate between different 
subtypes of CAP, e.g. by bacterial pathogen, bacterial vs. 
viral etiologies, or different risk classes, or to aid in deci-
sion-making regarding stopping or escalating antibiotic 
treatment. Of note, several biomarkers (although some-
what less accurate) were also identified for the clinically 
important differentiation between CAP and infection-
associated COPD exacerbation, and there was only par-
tial overlap with the top biomarkers for CAP vs. Controls. 
In addition, yet different PC species constituted the best 
biomarkers for COPD vs. Controls. These results sug-
gest (1) that plasma phospholipids merit further investi-
gation as biomarkers to help differentiate between CAP 
and COPD (or to potentially identify COPD patients with 
coexisting pneumonia) and (2) that the observed differ-
ences between CAP and COPD are not merely due to 
differences in the extent of inflammation-driven lipid 
reprogramming in the same direction, but that they also 
reflect inherent differences in pathophysiology between 
the two disease entities. Indeed, the heat maps shown 
in Fig. 2 also illustrate clear qualitative differences in the 
lipid concentration patterns of COPD and CAP as com-
pared with Controls. For instance, total SM and some 
individual SM were upregulated in COPD exacerbation 
only, which agrees well with previous reports of increased 
SM in COPD [30].
Curiously, regulation of AC concentrations differed 
from the other lipid classes in that the overall degree of 
change was the lowest and that only one (the short-chain 
AC valerylcarnitine, C5) fulfilled criteria for differential 
abundance, but did not correlate with CRP or PCT lev-
els. Studies in sepsis have suggested that increased levels 
of peripheral blood short-chain AC reflect organ dam-
age, notably of liver and kidney, and that increased acetyl 
carnitine (C2) concentrations are associated with mor-
tality [18]. Animal models of sepsis have suggested that 
this may be due to an acquired defect in fatty acid oxi-
dase [42]. Considering that none of our patients had poor 
outcomes, it remains to be studied whether ACs can be 
used to assess organ damage or clinical outcome in more 
severe CAP.
Potential impact of diet, age and sex
In agreement with the above mentioned studies on lipid 
biomarkers in acute infections, we did not collect data on 
food intake. Clinical experience shows that food intake is 
often markedly reduced in patients with acute illness, due 
to factors such as loss of appetite, physical weakness, or a 
medical indication for fasting status. It is therefore con-
ceivable that reduced food intake in the CAP and COPD 
groups (compared to the control subjects, who were 
healthy or presented to hospital for elective procedures) 
might have introduced a bias. However, we detected 
clear differences in lipid profiles even between these two 
acutely ill groups. In addition, it has been argued (per-
haps contrary to popular belief ) that effects of fasting sta-
tus on blood metabolite profiles are relatively weak and 
explain only a small fraction of metabolite variability [43]. 
Indeed, in a large study (n = 1197) no effects of fasting 
on saturated, mono- or poly-unsaturated phosphatidyl-
cholines were detected [44], but total poly-unsaturated 
phosphatidylcholines were clearly reduced in acute CAP 
in our study (Fig. 2c). In the same report, AC were found 
to be affected by fasting status, but in our study showed 
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the least variability among the three groups. In addition, 
in the aforementioned study on phospholipids in CAP, 
Müller et  al. found no differences in the concentrations 
of the assessed 75 phospholipids after a 14-h fast [20]. 
Taken together, these results indicate that, while we can-
not quantify the effects of differences in food intake on 
our results, they are likely to be minor compared to those 
of the primary diseases, CAP and COPD exacerbation. 
Age and sex are well documented variables affecting con-
centrations of several parameters measured with the Bio-
crates p180 kits [27], but both were well matched among 
the three groups in our study.
Limitations and strengths
Even though our results agree well with published evi-
dence, this study is clearly limited by the lack of an exter-
nal validation cohort and the relatively small sample 
sizes. Further research is therefore needed before the 
identified biomarkers can be advanced to clinical appli-
cation. This is particularly true for the COPD exacerba-
tion group, so that the results regarding COPD should 
be interpreted cautiously, including the diagnostic bio-
marker potential of the assayed lipid classes to differ-
entiate infection-associated COPD exacerbation from 
CAP or to detect pneumonia in COPD exacerbation. In 
addition, the study was not designed to assess longer-
term outcomes such as mortality after resolution of CAP, 
and due to the small proportion of patients with severe 
disease it was not feasible to screen for prognostic bio-
markers for complications. Considering that the human 
plasma lipidome contains at least 600 named and quan-
tifiable lipid species [45] (but probably many more [46]), 
our assays captured only a small part of the possible spec-
trum. On the other hand, our study differs from the other 
studies on phospholipids in CAP [19, 20] by the analysis 
of a broader spectrum of lipid classes and species, use 
of a well-matched control group, inclusion of infection-
associated COPD exacerbation as a clinically important 
disease control, and serial measurements within a rela-
tively narrow window after disease presentation. More-
over, to our knowledge it provides the first evidence of 
increased acid sphingomyelinase activity in pneumonia 
and COPD exacerbation in humans.
Conclusions
Our results clearly suggest that plasma phospholipids 
merit further evaluation as biomarkers for CAP as well as 
COPD, for instance by external validation of specific bio-
markers in larger, independent cohorts that are designed 
to address subgroup-specific outcomes. Moreover, it will 
now be of great interest to investigate how the balance 
between different phospholipid populations affects dis-
ease severity and organ damage and whether therapeutic 
interventions, such as transiently inhibiting acid sphingo-
myelinase activity to reduce levels of potentially damag-
ing ceramides, will improve clinical outcome.
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Additional file 1: Figure S1. Efficiency of analyte detection across 
all samples. The percentage of samples in which the analytes 
were detected > LOD is indicated by the fill darkness. All analytes 
detected > LOD in ≥ 75% of the samples (black and dark grey fill) were 
included in subsequent analyses. (A) Of the 145 potentially detectable 
lipids, 111 were detected > LOD in ≥ 75% of the samples. (B) The same 
lipids as in (A) but separated by lipid class. Detection efficiency was great‑
est for glycerophospholipids and sphingolipids. Figure S2. Contribution 
of each lipid analyte and indicator to the principal components PC1 
and PC2, and the square root of the sum of their squares. The higher the 
absolute value, the higher the influence on the principal component. 
(A) Analysis based on concentrations of all 111 lipid analytes; (B) PC only; 
(C) SM only; (D) AC only; (E) lysoPC only; and (F) 47 metabolic indicators. 
Results are arranged in descending order according to the PC’s values. 
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